Zimmer Biomet is a turnaround in orthopedics with the ROSA robotic platform driving share gains in hips and knees. Procedure volume recovery is steady but US pricing pressure persists. New CEO refocused on commercial execution and tuck-in M&A. China VBP impact has been absorbed. Re-rating requires sustained organic growth above 5%.
Thesis reviewed May 29, 2026
Zimmer Biomet Holdings is headquartered in United States, which is currently showing elevated risk signals.
🇺🇸United States78REDUCEView United States risk detail →🏥Healthcare34NEUTRAL| Ticker | Company | Score | Gap | Signal Δ | Action |
|---|---|---|---|---|---|
| TMO | Thermo Fisher Scientific Inc. | 38 | +11% | ↓3% | EARLY |
| SYK | Stryker Corporation | 38 | +15% | ↓3% | EARLY |
| TEVA | Teva Pharmaceutical Industries Ltd. | 38 | +9% | ↓3% | NEUTRAL |
| ELV | Elevance Health Inc. | 38 | +7% | ↓3% | NEUTRAL |
| CI | The Cigna Group | 38 | +9% | ↓3% | NEUTRAL |
| HCA | HCA Healthcare Inc. | 38 | +9% | ↓3% | EARLY |
| DHR | Danaher Corporation | 38 | +11% | ↓3% | EARLY |
Investors who hold ZBH may also have indirect exposure through these country funds.
Zimmer ROSA robotic placements set quarterly record
US knee procedure volumes grow 4% YoY in Q1
Estimates · Yahoo Finance · Not audited figures